Get started
Author

Stéphane Hominal

Observed names: S Hominal, S. Hominal, Stephane Hominal
ORCID: 0000-0002-4282-3377
Observed ORCID: 0000-0002-4282-3377
OpenAlex ID: A5082965263
Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study
2017 · Caroline Charlier, Élodie Perrodeau, et al. · The Lancet Infectious Diseases · 581
PDF
A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis
2004 · Line Claude, David Pérol, et al. · Radiotherapy and Oncology · 202
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)
2014 · Christos Chouaid, Cecile Dujon, et al. · Lung Cancer · 187
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies
2014 · T. Moran, J. Wei, et al. · Annals of Oncology · 32
Exogenous lipoid pneumonia with unusual CT pattern and FDG positron emission tomography scan findings
2002 · Florence Tahon, Yves Berthezène, et al. · European Radiology · 30
Weekly Paclitaxel Combined with Monthly Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Multicenter Phase II Study
2006 · Jean-Louis Pujol, Bernard Milleron, et al. · Journal of Thoracic Oncology · 26
PDF
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04–2021) trial
2024 · Olivier Bylicki, Florian Guisier, et al. · Lung Cancer · 23
PDF
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project
2020 · H. Blons, J.-B. Oudart, et al. · Lung Cancer · 19
PDF
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study
2024 · Hervé Léna, Laurent Greillier, et al. · The Lancet Respiratory Medicine · 18
LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer
2024 · Aurélie Swalduz, Camille Schiffler, et al. · Journal of Thoracic Oncology · 15
PDF
LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer.
2023 · Aurélie Swalduz, Hubert Curcio, et al. · Journal of Clinical Oncology · 14
Assessment of palliative care for advanced non-small-cell lung cancer in France: A prospective observational multicenter study (GFPC 0804 study)
2013 · Alain Vergnenègre, Stéphane Hominal, et al. · Lung Cancer · 14
Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting
2024 · Lionel Falchero, Nicolas Meyer, et al. · European Journal of Cancer · 11
Performance of an eHealth (NOMHAD) System Comprising Telemonitoring, Telenotification, and Telecoaching for Patients With Multimorbidity: Proof-of-Concept Study
2022 · Mathieu Chacornac, Aurélien Faoro, et al. · JMIR Formative Research · 10
PDF
Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study
2020 · T. Payen, J. Trédaniel, et al. · Respiratory Medicine and Research · 10
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)
2023 · Alain Vergnenegre, Isabelle Monnet, et al. · Lung Cancer · 9
Épidémiologie, prise en charge et coût des métastases osseuses des cancers bronchopulmonaires (hors métastases rachidiennes)
2013 · C. Decroisette, L.-M. Galerneau, et al. · Revue des Maladies Respiratoires · 7
Amélioration de la survie à 1 an dans le cancer du poumon en France. Résultats des études prospectives en vie réelle, KBP-2000-CPHG et KBP-2010-CPHG
2016 · M. Grivaux, B. Duvert, et al. · Revue de Pneumologie Clinique · 5
[Carcinomatous lymphangitis].
1999 · S Hominal, L Falchero, et al. · PubMed · 5
1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial
2024 · J. Ciccolini, M. Hamimed, et al. · Annals of Oncology · 2
PDF
Abstract LB120: Comprehensive biomarkers analysis to explain resistances to PD1-L1 ICIs: The precision immuno-oncology for advanced non-small cell lung cancer (PIONeeR) trial
2022 · Laurent Greillier, Florence Monville, et al. · Cancer Research · 2
MA16.09 Feasibility, Clinical Relevance of ALK/ROS1 Fusion Variant Detection by Liquid Biopsy in Advanced Non-Small Cell Lung Cancer
2018 · A. Swalduz, L. Mezquita, et al. · Journal of Thoracic Oncology · 2
PDF
Molecular heterogeneity assessment by NGS in non-small cell lung cancer (NSCLC) harboring EGFR mutations: Results of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study
2018 · H. Blons, J.-B. Oudart, et al. · Annals of Oncology · 2
Association épidémiologique entre pollution et altérations oncogéniques dans le cancer du poumon
2024 · S. Leblanc, M. Genin, et al. · Revue des Maladies Respiratoires Actualités · 1
1420P Real-life management of octogenarians with NSCLC in a French nationwide cohort
2023 · R. Corre, A-C. Neidhart, et al. · Annals of Oncology · 1
PDF
Works count: 62
Citation count: 1,235
H-index: 12
I10-index: 15
Year
Topic
Type